J&J’s Rybrevant-chemo combo shows positive PFS data in confirmatory study

John­son & John­son’s Ry­bre­vant met its pri­ma­ry end­point in a Phase III con­fir­ma­to­ry study test­ing the drug on pa­tients with new­ly di­ag­nosed ad­vanced or metasta­t­ic non-small cell lung can­cer (NSCLC) with EGFR ex­on 20 in­ser­tion mu­ta­tions, the com­pa­ny said in a topline da­ta re­lease Mon­day.

J&J com­pared a com­bo of chemother­a­py and Ry­bre­vant, which was the first drug ap­proved for pa­tients with the mu­ta­tion, with just chemother­a­py in the PA­PIL­LON study. The com­bo showed a “sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful im­prove­ment” in pro­gres­sion-free sur­vival, the com­pa­ny said.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN